Neurocrine Biosciences
NBIX
143.47
-2.04
-1.40%
Neurocrine Biosciences
US · NBIX
#1162 by market cap
Listed 1970
143.47
-2.04
-1.40%
Live - 5344 symbols - heartbeat 7s ago
· 2026-10-08 04:01
Pre-market
143.47
0.00%
After-hours
143.47
0.00%
Overnight
143.47
0.00%
- Market cap
- 14.58B
- P/E (TTM)i
- 20.98
- P/Bi
- 3.95
- EPSi
- 4.67
- Div yieldi
- 0.00%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on NBIX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 24 analysts
Buy
Avg price target
209.96 +46.3%
Price target rangecurrent 143.47
Low165.00
Avg209.96
High253.00
Buy 88%
Hold 13%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | Piper Sandler | -- | BUY | 210.00 |
| 2026-09-28 | UBS | -- | BUY | 214.00 |
| 2026-09-25 | Bernstein | -- | BUY | 218.00 |
| 2026-09-21 | RBC Capital | -- | BUY | 187.00 |
| 2026-09-14 | RBC Capital | -- | BUY | 198.00 |
| 2026-09-11 | Morgan Stanley | -- | HOLD | 183.00 |
| 2026-09-08 | RBC Capital | -- | BUY | 198.00 |
| 2026-09-04 | Citi | -- | BUY | 253.00 |
| 2026-09-03 | Citi | -- | BUY | 253.00 |
| 2026-08-24 | Morgan Stanley | -- | HOLD | 182.00 |
| 2026-08-17 | Evercore | -- | BUY | 215.00 |
| 2026-08-17 | BMO Capital | -- | HOLD | 190.00 |
| 2026-08-13 | Morgan Stanley | -- | HOLD | 182.00 |
| 2026-08-13 | Deutsche Bank | -- | HOLD | 165.00 |
| 2026-08-12 | Bernstein | -- | BUY | 218.00 |
| 2026-08-12 | BMO Capital | -- | HOLD | 190.00 |
| 2026-08-06 | J.P. Morgan | -- | BUY | 217.00 |
| 2026-08-03 | CCORF | -- | BUY | 210.00 |
| 2026-08-03 | Truist Financial | -- | BUY | 213.00 |
| 2026-08-03 | Wedbush | -- | BUY | 194.00 |
| 2026-08-03 | Citi | -- | BUY | 249.00 |
| 2026-07-31 | TD Cowen | -- | BUY | 220.00 |
| 2026-07-31 | Wells Fargo | -- | BUY | 200.00 |
| 2026-07-31 | William Blair | -- | BUY | -- |
| 2026-07-31 | UBS | -- | BUY | 231.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
A+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-08.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-08 | Morgan Stanley | BUY → HOLD | 175.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | After close | ±8.09% | -10.08% (beat) |
| 2026/Q1 | 2026-05-05 | After close | ±7.44% | +8.86% (beat) |
| 2025/Q4 | 2026-02-11 | After close | ±6.70% | -10.43% (beat) |
| 2025/Q3 | 2025-10-28 | After close | ±8.87% | -6.35% (in line) |
| 2025/Q2 | 2025-07-30 | After close | ±9.19% | -6.24% (in line) |
| 2025/Q1 | 2025-05-05 | After close | ±12.38% | +8.36% (in line) |
| 2024/Q4 | 2025-02-06 | After close | ±7.76% | -18.53% (beat) |
| 2024/Q3 | 2024-10-30 | -- | ±8.10% | +7.01% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±16.25% | +8.18% (in line) |
| 2024/Q1 | 2024-05-01 | -- | ±7.33% | +3.99% (in line) |
| 2023/Q4 | 2024-02-07 | -- | ±7.12% | -4.67% (in line) |
| 2023/Q3 | 2023-10-31 | -- | ±9.48% | +3.56% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:01:04 · For reference only, not investment advice and not tailored to your situation.